ACET

Stats

Summary

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v

Market Cap: 181 Million

Primary Exchange: NASDAQ

Website: https://www.adicetbio.com/

Shares Outstanding: 75.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.9384754027720835

Sector: Manufacturing

Industry: Medicinal and Botanical Manufacturing

Ethical Flags

Longest drawdown: 2132 trading days

From: 2015-10-29 To: 2024-03-07

Lowest Point: